Sema4 Holdings Corp (NASDAQ:SMFR) reported Q4 revenues of $57.8 million, down 9.6% Y/Y, beating the consensus of $49.66 million due to lower volumes in COVID-19 business.
- Total revenue increased 24% in the fourth quarter of 2021 (excluding COVID-19 testing revenue).
- Diagnostic testing volumes were up 37%, with 82,966 tests resulted (excluding COVID-19 tests), including 142% growth in Oncology and 33% growth in Women's Health.
- Diagnostic test revenue was $56.13 million, down 8.9%.
- Sema4 reported a Q4 Basic EPS loss of $(0.17).
- The company held $400.6 million in cash and equivalents.
- Guidance: Sema4 expects FY22 revenues of $215 million - $225 million (consensus of $273.57 million).
- The company expects FY22 resulted test volume growth to exceed 20% (excluding COVID-19 tests), with an adjusted gross margin of over 10%.
- Price Action: SMFR shares closed 6.69% lower at $2.65 on Monday.
